ViewRay Systems, Inc. designs, manufactures, and markets magnetic resonance imaging radiation therapy system in the United States and internationally. The company offers MRIdian A3i, an MRI-guided radiation therapy system that provides real-time 3D tissue tracking and automated beam control. Its product is used for the treatment of pancreas, prostate, lung, liver, breast, and oligometastatic cance...
ViewRay reported revenue of $102.21 million for fiscal year 2022, up 45.8% from fiscal year 2021, and net income of -$107.33 million. In Q1 2023 (the quarter ended March 31, 2023) revenue was $22.53 million, up 19.4% from a year before. Its largest business segment, Product, brought in 78% of segment revenue in fiscal year 2022; UNITED STATES was the largest region with 51%. Its market capitalization was $18,340 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2022; market data as of October 8, 2026.
No profile data available.